Literature DB >> 32585616

Outcomes and future directions for neuroimmunology/multiple sclerosis fellowship training: Survey of recent trainees.

Le H Hua1, Ahmed Z Obeidat2, Erin E Longbrake3.   

Abstract

BACKGROUND: Neuroimmunology/multiple sclerosis is a rapidly evolving, but still poorly defined subspecialty. Fellowship training is not standardized, and there is substantial variability across sites. Outcomes of fellowship training have not yet been studied. We therefore examined early career choices of neuroimmunology/MS fellowship program graduates and solicited the perspective of current and recent trainees on their fellowship experience as well as opportunities to improve neuroimmunology education.
METHODS: We developed a questionnaire to collect information about fellowship training experiences and current medical practice. We identified recent graduates based on records from US training programs and the National MS Society and electronically sent the survey to current trainees and recent graduates (within the last 5 years).
RESULTS: We identified 179 current/recent trainees and successfully reached 157 with survey distributions. Ninety-five individuals (60.5%) returned surveys. Most graduates assumed an academic practice (68%) focused mostly or exclusively on MS and other CNS neuroimmune diseases (55%), and practiced in regions where there were ≥5 other neuroimmunology specialists (51%). Graduates felt well-prepared to manage diagnoses of MS and neuromyelitis optica spectrum disorders but their comfort with rarer CNS neuroimmune diseases varied substantially. Basic immunology, neuro-rheumatology, grant writing and neuro-rehabilitation were identified as high impact areas for cross-disciplinary didactic training. The majority of recent trainees (57%) favored standardizing a core neuroimmunology curriculum, and 48% favored developing a subspecialty certification.
CONCLUSIONS: This is the first study to examine practice outcomes and trainee experiences for neuroimmunology training programs. We anticipate that these data will help educators define a core curriculum for the subspecialty and identify complementary skill sets that enhance the traditional clinic-based model of teaching.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Graduate medical education; Multiple sclerosis; Neuroimmunology

Year:  2020        PMID: 32585616      PMCID: PMC8023409          DOI: 10.1016/j.msard.2020.102296

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  9 in total

Review 1.  Evolving concepts in the treatment of relapsing multiple sclerosis.

Authors:  Giancarlo Comi; Marta Radaelli; Per Soelberg Sørensen
Journal:  Lancet       Date:  2016-11-24       Impact factor: 79.321

2.  Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder.

Authors:  Takashi Yamamura; Ingo Kleiter; Kazuo Fujihara; Jacqueline Palace; Benjamin Greenberg; Beata Zakrzewska-Pniewska; Francesco Patti; Ching-Piao Tsai; Albert Saiz; Hayato Yamazaki; Yuichi Kawata; Padraig Wright; Jerome De Seze
Journal:  N Engl J Med       Date:  2019-11-28       Impact factor: 91.245

Review 3.  Autoantibody-Associated Central Nervous System Neurologic Disorders.

Authors:  Jenny Linnoila; Sean J Pittock
Journal:  Semin Neurol       Date:  2016-09-19       Impact factor: 3.420

4.  Emerging Subspecialties in Neurology: Autoimmune neurology.

Authors:  A Sebastian López-Chiriboga; Stacey L Clardy
Journal:  Neurology       Date:  2017-09-11       Impact factor: 9.910

5.  Multidisciplinary management of multiple sclerosis symptoms.

Authors:  Philippe Gallien; Jordi Gich; Bernardo F Sánchez-Dalmau; Wolfgang Feneberg
Journal:  Eur Neurol       Date:  2014-09-26       Impact factor: 1.710

6.  Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.

Authors:  Sean J Pittock; Achim Berthele; Kazuo Fujihara; Ho Jin Kim; Michael Levy; Jacqueline Palace; Ichiro Nakashima; Murat Terzi; Natalia Totolyan; Shanthi Viswanathan; Kai-Chen Wang; Amy Pace; Kenji P Fujita; Róisín Armstrong; Dean M Wingerchuk
Journal:  N Engl J Med       Date:  2019-05-03       Impact factor: 91.245

7.  Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.

Authors:  Bruce A C Cree; Jeffrey L Bennett; Ho Jin Kim; Brian G Weinshenker; Sean J Pittock; Dean M Wingerchuk; Kazuo Fujihara; Friedemann Paul; Gary R Cutter; Romain Marignier; Ari J Green; Orhan Aktas; Hans-Peter Hartung; Fred D Lublin; Jorn Drappa; Gerard Barron; Soraya Madani; John N Ratchford; Dewei She; Daniel Cimbora; Eliezer Katz
Journal:  Lancet       Date:  2019-09-05       Impact factor: 79.321

8.  Education Research: Multiple sclerosis and neuroimmunology fellowship training status in the United States.

Authors:  Ahmed Z Obeidat; Yasir N Jassam; Le H Hua; Gary Cutter; Corey C Ford; June Halper; Robert P Lisak; Nancy L Sicotte; Erin E Longbrake
Journal:  Neurology       Date:  2020-02-27       Impact factor: 11.800

Review 9.  The Multiple Sclerosis Care Unit.

Authors:  Per Soelberg Sorensen; Gavin Giovannoni; Xavier Montalban; Christoph Thalheim; Paola Zaratin; Giancarlo Comi
Journal:  Mult Scler       Date:  2018-10-23       Impact factor: 6.312

  9 in total
  1 in total

1.  Consensus Curriculum for Fellowship Training in Multiple Sclerosis and Neuroimmunology.

Authors:  Le H Hua; Ahmed Z Obeidat; Lilyana Amezcua; Jeffrey A Cohen; Kathleen Costello; Jeffrey Dunn; Jeffrey M Gelfand; Myla D Goldman; Sarah Hopkins; Douglas Jeffery; Stephen Krieger; Scott D Newsome; Suma Shah; Nancy L Sicotte; Vijayshree Yadav; Erin E Longbrake
Journal:  Neurol Clin Pract       Date:  2021-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.